type-1 interferon

临床试验

计划入组 55 人 · 首次发布于 2022 年 7 月 28 日

已完成

NCT00436046

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

计划入组 95 人 · 首次发布于 2007 年 2 月 16 日

尚未招募

NCT06784076

Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue

计划入组 20 人 · 首次发布于 2025 年 1 月 20 日

药物

查看全部 7905 →

endogenous reverse transcriptase inhibitors (type 1 interferonopathies)

Biotech

Approved

Anifrolumab(Saphnelo)

相关疾病：Moderate Systemic Lupus Erythematosus (SLE), Severe Systemic Lupus Erythematosus (SLE)

Biotech

Investigational

Human interferon omega-1

机构

查看全部 1404 →

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

资讯

查看全部 17499 →

去年

ROME Therapeutics Presents Data on LINE-1 Reverse Transcriptase Inhibitors for Autoimmune Diseases

去年

ROME Therapeutics Presents Data on LINE-1 Reverse Transcriptase Inhibitors for Autoimmune Diseases

11个月前

临床试验

Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue

药物

endogenous reverse transcriptase inhibitors (type 1 interferonopathies)

Anifrolumab(Saphnelo)

Human interferon omega-1

机构

NHI-1

Xi'an No.1 Hospital

ALPHA-1 FOUNDATION, INC.

资讯

ROME Therapeutics Presents Data on LINE-1 Reverse Transcriptase Inhibitors for Autoimmune Diseases

ROME Therapeutics Presents Data on LINE-1 Reverse Transcriptase Inhibitors for Autoimmune Diseases

Dianthus Therapeutics Secures Exclusive License for DNTH212, a Dual-Target Autoimmune Therapy